Survival by Response to First-line Platinum-Based Therapy Among Patients With Extensive Disease Small Cell Lung Cancer

被引：0

作者：

Danese, M. ^{[1
]}

Gleeson, M. ^{[1
]}

Lubeck, D. ^{[1
]}

Penrod, J. ^{[2
]}

Korytowsky, B. ^{[2
]}

Yuan, Y. ^{[2
]}

机构：

[1] Outcomes Insights Inc, Westlake Village, CA USA

[2] Bristol Myers Squibb, Princeton, NJ USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

small cell lung cancer; overall survival; platinum-based therapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.15-003

引用

页码：S2043 / S2043

页数：1

共 50 条

[31] Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Rizvi, Naiyer A.
Hellmann, Matthew D.
Brahmer, Julie R.
Juergens, Rosalyn A.
Borghaei, Hossein
Gettinger, Scott
Chow, Laura Q.
Gerber, David E.
Laurie, Scott A.
Goldman, Jonathan W.
Shepherd, Frances A.
Chen, Allen C.
Shen, Yun
Nathan, Faith E.
Harbison, Christopher T.
Antonia, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2969 - +
[32] Topotecan as first-line therapy for small cell lung cancer
Greco, FA
LUNG CANCER, 2003, 41 : S9 - S16
[33] Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer
Liu, Hongbing
Wu, Ying
Wang, Zhaofeng
Yao, Yanwen
Chen, Fangfang
Zhang, He
Wang, Yunfen
Song, Yong
JOURNAL OF THORACIC DISEASE, 2013, 5 (06) : 783 - 789
[34] Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients
Song, Ying-Jian
Wang, Li-Xin
Hong, Yong-Qing
Lu, Zheng-Hong
Tong, Qiang
Fang, Xiao-Zheng
Tan, Juan
TUMOR BIOLOGY, 2016, 37 (04) : 5285 - 5293
[35] Exosome inhibition improves response to first-line therapy in small cell lung cancer
Irep, Nesrin
Inci, Kubilay
Tokgun, Pervin Elvan
Tokgun, Onur
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (04)
[36] High glasgow prognostic score associates with a poor survival in Chinese advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy
Su, Keju
Wang, Xu
Chi, Lumei
Liu, Yang
Jin, Lina
Li, Wei
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (08): : 16353 - 16359
[37] Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update
Ettinger, D. S.
Jotte, R.
Lorigan, P.
Gupta, V.
Garbo, L.
Conkling, P.
Spigel, D.
McNally, R.
Renschler, M.
Oliver, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[38] The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy
Liu, Xiaofan
Zhang, Weiming
Yin, Wen
Xiao, Yang
Zhou, Changzhi
Hu, Yi
Geng, Shuang
MEDICINE, 2017, 96 (46)
[39] The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy
Lee, Siow Ming
Upadhyay, Sunil
Lewanski, Conrad
Falk, Stephen
Skailes, Geraldine
Woll, Penella J.
Hatton, Matthew
Lal, Rohit
Jones, Richard
Toy, Elizabeth
Rudd, Robin
Ngai, Yenting
Edwards, Alex
Hackshaw, Allan
EUROPEAN JOURNAL OF CANCER, 2019, 120 : 86 - 96
[40] Curative efficacy might be an early predictor of prognosis in patients with small cell lung cancer treated with 2 cycles of platinum-based first-line chemotherapy
Zhu, Kaibo
Jiang, Minlin
Xu, Yi
Chen, Peixin
Wang, Hao
Yu, Jia
Zhu, Jun
Zhao, Wencheng
Meng, Die
He, Yayi
JOURNAL OF THORACIC DISEASE, 2021, 13 (02) : 1205 - 1214

← 1 2 3 4 5 →